` CEPS (CTI Biopharma Corp) vs DAX Index Comparison - Alpha Spread

C
CEPS
vs
D
DAX Index

Over the past 12 months, CEPS has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +31% growth.

Stocks Performance
CEPS vs DAX Index

Loading
CEPS
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
CEPS vs DAX Index

Performance Gap Between CEPS and GDAXI
HIDDEN
Show

Performance By Year
CEPS vs DAX Index

Loading
CEPS
DAX Index
Add Stock

Competitors Performance
CTI Biopharma Corp vs Peers

DAX Index
CEPS
ABBV
AMGN
GILD
VRTX
Add Stock

CTI Biopharma Corp
Glance View

Market Cap
3.7B EUR
Industry
Biotechnology

CTI BioPharma Corp. began its journey with a singular focus on transforming the landscape of treatment for blood-related cancers. Established with a commitment to innovation in the biotechnology sector, the Seattle-based company has strategically positioned itself as a pivotal player in developing novel therapies for hematologic malignancies. At the heart of its operations is its flagship product, Pixuvri (pixantrone), which gained initial traction in the European market as a treatment for certain types of aggressive non-Hodgkin lymphoma. This approval represented not only a milestone for the company but also a validation of its dedicated approach in addressing critical unmet needs within oncology. The company's revenue model pivots on the successful commercialization of its pharmaceutical innovations. Through strategic collaborations and licensing agreements, CTI BioPharma seeks to broaden the distribution reach and accessibility of its treatments. By leveraging partnerships within the pharmaceutical industry, CTI has aimed to augment its research capabilities and expand its market presence. This business approach underscores a sustainable pathway to profitability by aligning its innovations directly with the needs of healthcare providers and patients, thus ensuring that its scientific advances translate into tangible therapeutic options in the oncology space. By continually refining its product portfolio, the company maintains a dynamic stance in a rapidly evolving market, safeguarding its position and ensuring its growth trajectory.

CEPS Intrinsic Value
Not Available
Back to Top